CPhl China 2023 Invitation

2023/04/20

Related News

Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO
March 7, 2023Recently, Zhejiang Haichang Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received a registration certificate for its active pharmaceutical ingredient product from ...view
Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation
July 27, 2021Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.view
New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation
December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
Beilu Pharma Established a Wholly-owned R&D Subsidiary
September 7, 2022Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...view
【New Product】Beilu Pharmaceutical's Gadoteric Acid Meglumine Injection and API Approved
July 11, 2024Recently, Beilu Pharmaceuticals received the Drug Registration Certificate for Gadopentetate Dimeglumine Injection and the approval notice for the marketing application of Gadopentetate Dimeglumine as...view
Beilu's Iopamidol Injection Won the Bid for China's Pharmaceutical Centralized Procurement
July 15, 2022On July 12, 2022, Beilu participated in the seventh batch of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use Joint Procurement Off...view

CPhl China 2023 Invitation

Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO

Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation

New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation

Beilu Pharma Established a Wholly-owned R&D Subsidiary

【New Product】Beilu Pharmaceutical's Gadoteric Acid Meglumine Injection and API Approved

Beilu's Iopamidol Injection Won the Bid for China's Pharmaceutical Centralized Procurement